Literature DB >> 34000267

Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona.

Ariella P Dale1, Matthew Hudson2, Theresa Cullen3, Katherine Ellingson4, Kat Davis3, Darunee Armenta5, Heather Friebus5, Chase Currie6, Rachana Bhattarai6, Shane Brady6, Ken Komatsu6, Nimalie Stone7, Timothy Uyeki7, Kara Jacobs Slifka7, Carlos Perez-Velez3, Amelia Keaton7.   

Abstract

Entities:  

Year:  2021        PMID： 34000267     DOI： 10.1016/j.jamda.2021.04.023

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN： 1525-8610            Impact factor:   4.669


× No keyword cloud information.
  2 in total

Review 1.  SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.

Authors:  Nina Kreuzberger; Caroline Hirsch; Khai Li Chai; Eve Tomlinson; Zahra Khosravi; Maria Popp; Miriam Neidhardt; Vanessa Piechotta; Susanne Salomon; Sarah J Valk; Ina Monsef; Christoph Schmaderer; Erica M Wood; Cynthia So-Osman; David J Roberts; Zoe McQuilten; Lise J Estcourt; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2021-09-02

2.  Clinical outcomes of monoclonal antibody therapy during a COVID-19 outbreak in a skilled nursing facility-Arizona, 2021.

Authors:  Ariella P Dale; Matthew J Hudson; Darunee Armenta; Heather Friebus; Katherine D Ellingson; Kat Davis; Theresa Cullen; Shane Brady; Kenneth K Komatsu; Nimalie D Stone; Timothy M Uyeki; Kara Jacobs Slifka; Carlos M Pérez-Vélez; Amelia A Keaton
Journal:  J Am Geriatr Soc       Date:  2022-03-03       Impact factor: 7.538
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.